Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Mar 7:15:5.
doi: 10.1186/s12948-017-0058-3. eCollection 2017.

Pharmacoeconomics of sublingual immunotherapy with the 5-grass pollen tablets for seasonal allergic rhinitis

Carlo Lombardi  1 , Valerie Melli  2 , Cristoforo Incorvaia  3 , Erminia Ridolo  2
Affiliations
Review

Pharmacoeconomics of sublingual immunotherapy with the 5-grass pollen tablets for seasonal allergic rhinitis

Carlo Lombardi et al. Clin Mol Allergy. .

Abstract

Allergic rhinitis has a very high burden regarding both direct and indirect costs. This makes essential in the management of AR to reduce the clinical severity of the disease and thus to lessen its costs. This particularly concerns allergen immunotherapy (AIT), that, based on its immunological action on the causes of allergy, extends its benefit also after discontinuation of the treatment. From the pharmacoeconomic point of view, any treatment must be evaluated according to its cost-effectiveness, that is, the ratio between the cost of the intervention and its effect. A favorable cost-benefit ratio for AIT was defined, starting from the first studies in the 1990s on subcutaneous immunotherapy (SCIT) in AR patients, that highlighted a clear advantage on costs over the treatment with symptomatic drugs. Such outcome was confirmed also for sublingual immunotherapy (SLIT), that has also the advantage on SCIT to be free of the cost of the injections. Here we review the available literature on pharmacoeconomic data for SLIT with the 5-grass pollen tablets.

Keywords: Allergen immunotherapy; Allergic rhinitis; Cost-effectiveness; Pharmacoeconomics; Sublingual immunotherapy.

PubMed Disclaimer

References

    1. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variation in prevalence of symptoms of asthma, allergic rhino conjunctivitis, and atopic eczema. Lancet. 1998;351:1225–1232. doi: 10.1016/S0140-6736(97)07302-9. - DOI - PubMed
    1. Sly RM. Changing prevalence of allergic rhinitis and asthma. Ann Allergy Asthma Immunol. 1999;82:233–248. doi: 10.1016/S1081-1206(10)62603-8. - DOI - PubMed
    1. Upton MN, McConnachie A, McSharry C, et al. Intergenerational 20 year trends in the prevalence of asthma and hay fever in adults: the Midspan family study survey of parents and offspring. BMJ. 2000;321:88–92. doi: 10.1136/bmj.321.7253.88. - DOI - PMC - PubMed
    1. Linneberg A, Nielsen NH, Madsen F, et al. Increasing prevalence of specific IgE to aeroallergens in an adult population: two cross-sectional studies 8 years apart; the Copenhagen Allergy Study. J Allergy Clin Immunol. 2000;106:247–252. doi: 10.1067/mai.2000.108312. - DOI - PubMed
    1. Dalal AA, Stanford R, Henry H, et al. Economic burden of rhinitis in managed care: a retrospective claims data analysis. Ann Allergy Asthma Immunol. 2008;101:23–29. doi: 10.1016/S1081-1206(10)60830-7. - DOI - PubMed

LinkOut - more resources